The goal of this clinical trial is to compare the therapeutic effects of chemotherapy followed by surgery and surgery followed by chemotherapy in patients with locally advanced breast cancer(LABC). Patients with LABC will be randomly divided into two groups, each receiving chemotherapy followed by surgery or surgery followed by chemotherapy. The main comparison was between the disease-free survival (DFS) of two groups of patients, with the secondary study endpoint being overall survival (OS); Five year survival; Local recurrence or distant metastasis rate.
Local advanced breast cancer was enrolled in the Department of Breast Surgery of Peking Union Medical College Hospital and Beijing Cooperation Hospital according to the criteria for patient inclusion. It is estimated that 50 patients will be enrolled. Randomly divide patients into two groups. The plan for Group A (experimental group, 25 cases) is "surgery+systematic treatment"; The plan for Group B (control group, 25 cases) is "neoadjuvant therapy+surgery+systematic treatment". Based on the previously obtained patient personal information, treatment related information, tumor tissue/blood sample test results, statistical analysis was conducted to explore the impact of different treatment strategies for locally advanced breast cancer on the survival and prognosis of patients.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
50
Modified radical mastectomy for breast cancer
neoadjuvant chemotherapy(Drugs:" Doxorubicin""Paclitaxel""Albumin paclitaxel""Cyclophosphamide"), endocrine therapy(Drugs:"Toremifen""Zoladex""Aromatase inhibitors"), targeted therapy(Drugs:"trastuzumab""Pertuzumab")
chemotherapyDrugs:" Doxorubicin""Paclitaxel""Albumin paclitaxel""Cyclophosphamide"), endocrine therapy(Drugs:"Toremifen""Zoladex""Aromatase inhibitors"), targeted therapy(Drugs:"trastuzumab""Pertuzumab"),radiotherapy("Yikeda Versa HD linear accelerator""Varian Trilogy linear accelerator")
Ying Xu
Beijing, China
RECRUITINGDFS
Disease-free survival of patients with locally advanced breast cancer
Time frame: 1 year;3 years;5 years
OS
Overall survival of patients with locally advanced breast cancer
Time frame: 1 year;3 years;5 years
Five year survival rate
Five year survival rate of patients with locally advanced breast cancer
Time frame: 1 year;3 years;5 years
Local recurrence or distant metastasis rate
Local recurrence or distant metastasis rate of patients with locally advanced breast cancer
Time frame: 1 year;3 years;5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.